샘플 요청 목록

 카트 문의
시장보고서
상품코드
1781366

세계의 고분자 의약품 CDMO 시장

Large Molecule Drug Substance CDMO
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 378 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

고분자 의약품 CDMO 세계 시장은 2030년까지 203억 달러에 달할 전망

2024년에 133억 달러로 추정되는 고분자 의약품 CDMO 세계 시장은 2024년부터 2030년까지 CAGR 7.2%로 성장하여 2030년에는 203억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 위탁생산 서비스는 CAGR 6.0%를 기록하며 분석 기간 종료시에는 125억 달러에 달할 것으로 예측됩니다. 위탁개발 서비스 분야의 성장률은 분석 기간 동안 CAGR 9.4%로 추정됩니다.

미국 시장은 36억 달러, 중국은 CAGR 11.1%로 성장할 것으로 예측

미국의 고분자 의약품 CDMO 시장은 2024년에 36억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 42억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.7%와 6.9%로 예측됩니다. 유럽에서는 독일이 CAGR 4.8%로 성장할 것으로 예측됩니다.

세계의 고분자 의약품 CDMO 시장 - 주요 동향과 촉진요인 정리

고분자 의약품 CDMO 시장은 바이오의약품의 발전과 함께 어떻게 진화하고 있는가?

고분자 의약품 위탁개발생산(CDMO) 시장은 생물학적 제제, 바이오시밀러, 첨단 치료제에 대한 수요 증가로 인해 빠르게 변화하고 있습니다. 단클론항체, 재조합 단백질, 세포 및 유전자 치료의 부상으로 복잡한 고분자 제조를 지원할 수 있는 전문 CDMO 서비스에 대한 강력한 수요가 발생하고 있습니다. 일회용 바이오프로세싱 기술의 발달로 보다 유연하고 확장 가능한 제조 솔루션이 가능해져 제약 개발 기업의 비용과 납기를 단축할 수 있게 되었습니다. 또한, 바이오 공정에서 인공지능과 머신러닝의 통합은 공정 최적화, 품질 관리, 예지보존을 강화하고 있습니다. 규제 당국이 생물학적 제제 제조 가이드라인을 강화하는 가운데, CDMO는 제품의 안전성과 유효성을 보장하기 위해 고효율 정제 기술, 분석 개발, 컴플라이언스 중심의 워크플로우에 투자하고 있습니다. 이러한 산업 역학의 진화로 인해, 거대 분자 CDMO는 의약품 개발 및 상용화를 가속화하고자 하는 바이오제약 기업에게 필수적인 파트너로 자리매김하고 있습니다.

고분자 CDMO 서비스에 대한 수요가 증가하는 이유는 무엇인가?

치료 파이프라인에서 바이오의약품과 바이오시밀러에 대한 의존도가 높아짐에 따라 고분자 CDMO 서비스에 대한 수요가 크게 증가하고 있습니다. 제약사들은 CDMO의 전문성, 첨단 인프라, 규제 준수 능력을 활용하기 위해 CDMO에 개발 및 제조 업무를 위탁하는 사례가 늘고 있습니다. 발효, 세포배양, 정제 공정을 포함한 고분자 의약품의 제조는 복잡하기 때문에 최첨단 설비를 갖춘 고도의 기술력을 갖춘 수탁 제조업체의 참여가 필요합니다. 또한, 블록버스터 바이오의약품의 특허 만료로 인한 바이오시밀러의 확대는 공정 개발 및 스케일업 제조에 대한 CDMO 서비스 수요를 촉진하고 있습니다. 맞춤형 의료, 표적 생물학적 치료와 같은 새로운 트렌드도 제약회사들이 맞춤형 제조 솔루션을 찾는 가운데 시장 성장에 기여하고 있습니다. 또한, 세계 공급망의 혼란은 생물학적 제제 제조의 연속성을 보장하기 위해 탄력적이고 지리적으로 다양한 CDMO 파트너십의 필요성을 강조하고 있습니다. 바이오의약품 연구개발에 대한 투자가 증가함에 따라 CDMO는 업계의 진화하는 요구에 부응하는 데 중요한 역할을 하고 있습니다.

고분자 CDMO의 성장에 영향을 미치는 과제는 무엇인가?

시장의 강력한 성장에도 불구하고, 고분자 CDMO는 사업 확장 및 운영 효율성에 영향을 미칠 수 있는 몇 가지 도전에 직면해 있습니다. 주요 과제 중 하나는 클린룸, 바이오리액터, 정제 시스템 등 첨단 바이오의약품 제조 시설의 구축 및 유지에 드는 높은 비용입니다. 고분자 의약품 제조에 대한 엄격한 규제 환경은 CDMO가 지속적으로 변화하는 컴플라이언스 요건에 적응해야 하기 때문에 업무를 더욱 복잡하게 만들고 있습니다. 생산능력의 제약도 큰 문제이며, 고분자 의약품 위탁생산에 대한 수요 증가는 가용한 생산 인프라를 초과하고 있습니다. 이에 대응하기 위해 CDMO는 제조 거점을 확장하고, 모듈식 바이오프로세싱 및 연속 제조 기술과 같은 유연한 제조 플랫폼에 투자하고 있습니다. 고분자 의약품 개발은 복잡하기 때문에 고도의 분석 능력과 공정 특성 평가에 대한 전문 지식이 필요하며, 기술적 과제가 더욱 증가하고 있습니다. 또한, 바이오프로세스 엔지니어링 및 규제 준수 분야의 인력 부족은 CDMO가 효율적으로 사업을 확장하는 능력에 영향을 미치고 있습니다. 이러한 과제를 극복하는 것은 지속가능한 성장을 보장하고 고분자 CDMO 서비스에 대한 수요 증가에 대응하는 데 있어 매우 중요합니다.

고분자 CDMO 시장 확대의 원동력은?

고분자 CDMO 시장의 성장은 생물학적 제제의 채택 증가, 바이오의약품에 대한 투자 증가, 제조 기술 발전 등 여러 요인에 의해 주도되고 있습니다. 단클론항체, 백신, 세포 및 유전자 치료제에 대한 수요가 급증하면서 복잡한 바이오 제조 공정에 대응할 수 있는 전문 CDMO 서비스의 필요성이 대두되고 있습니다. 제약회사가 의약품 제조를 위한 비용 효율적이고 확장 가능한 솔루션을 찾고 있기 때문에 제약회사와 CDMO 간의 개발 위탁 파트너십이 확대되고 있습니다. 규제 당국 또한 생물학적 제제 제조의 품질, 안전성, 효율성을 촉진하는 가이드라인을 제정함으로써 시장 성장을 촉진하는 데 중요한 역할을 하고 있습니다. 맞춤형 의료와 정밀 바이오의약품을 향한 트렌드의 증가로 CDMO는 일회용 시스템, 고처리량 스크리닝 플랫폼과 같은 유연한 제조 기술에 대한 투자를 촉진하고 있습니다. 또한, 공정 자동화, AI 기반 분석, 스마트 바이오프로세싱의 발전은 효율성을 높이고 제조 비용을 절감하고 있습니다. 제약사들이 리스크를 줄이고 자원을 최적화하기 위해 아웃소싱으로 전환하는 가운데, 고분자 CDMO 시장은 지속적인 성장세를 보이며 바이오의약품 제조의 미래를 만들어 갈 준비가 되어 있습니다.

부문

서비스(위탁생산 서비스, 위탁개발 서비스), 소스(포유류 소스, 미생물 소스, 기타 소스), 최종사용자(바이오테크놀러지 기업 최종사용자, CRO 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Abzena
  • AGC Biologics
  • Avid Bioservices
  • BioVectra
  • Boehringer Ingelheim BioXcellence
  • Catalent, Inc.
  • Emergent BioSolutions
  • Eurofins Scientific
  • FUJIFILM Diosynth Biotechnologies
  • JHL Biotech
  • KBI Biopharma
  • Lonza Group
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Siegfried Holding AG
  • Syngene International
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec
  • WuXi Biologics

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.07

Global Large Molecule Drug Substance CDMO Market to Reach US$20.3 Billion by 2030

The global market for Large Molecule Drug Substance CDMO estimated at US$13.3 Billion in the year 2024, is expected to reach US$20.3 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Contract Manufacturing Service, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$12.5 Billion by the end of the analysis period. Growth in the Contract Development Service segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 11.1% CAGR

The Large Molecule Drug Substance CDMO market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Large Molecule Drug Substance CDMO Market - Key Trends & Drivers Summarized

How Is the Large Molecule Drug Substance CDMO Market Evolving with Biopharmaceutical Advancements?

The large molecule contract development and manufacturing organization (CDMO) market is undergoing rapid transformation, driven by the increasing demand for biologics, biosimilars, and advanced therapies. The rise of monoclonal antibodies, recombinant proteins, and cell and gene therapies has created a strong need for specialized CDMO services that can support complex large molecule manufacturing. Advancements in single-use bioprocessing technologies are enabling more flexible and scalable production solutions, reducing costs and turnaround times for drug developers. Additionally, the integration of artificial intelligence and machine learning in bioprocessing is enhancing process optimization, quality control, and predictive maintenance. As regulatory agencies tighten guidelines for biologics manufacturing, CDMOs are investing in high-efficiency purification techniques, analytical development, and compliance-driven workflows to ensure product safety and efficacy. These evolving industry dynamics are positioning large molecule CDMOs as indispensable partners for biopharmaceutical companies looking to accelerate drug development and commercialization.

Why Is Demand for Large Molecule CDMO Services Increasing?

The growing reliance on biologics and biosimilars in therapeutic pipelines has significantly increased the demand for large molecule CDMO services. Pharmaceutical companies are increasingly outsourcing development and manufacturing activities to CDMOs to leverage their specialized expertise, advanced infrastructure, and regulatory compliance capabilities. The complexity of large molecule drug manufacturing, including fermentation, cell culture, and purification processes, necessitates the involvement of highly skilled contract manufacturers with state-of-the-art facilities. Additionally, the expansion of biosimilars, driven by patent expirations of blockbuster biologics, has fueled demand for CDMO services in process development and scale-up manufacturing. Emerging trends such as personalized medicine and targeted biologic therapies are also contributing to market growth, as pharmaceutical companies seek customized manufacturing solutions. Furthermore, global supply chain disruptions have highlighted the need for resilient and geographically diverse CDMO partnerships to ensure continuity in biologics production. With increasing investments in biopharmaceutical R&D, CDMOs are playing a crucial role in meeting the industry’s evolving needs.

What Challenges Are Impacting the Growth of Large Molecule CDMOs?

Despite strong market growth, large molecule CDMOs face several challenges that could impact their expansion and operational efficiency. One of the primary challenges is the high cost of establishing and maintaining advanced biopharmaceutical manufacturing facilities, including cleanrooms, bioreactors, and purification systems. The stringent regulatory landscape for large molecule drug manufacturing further complicates operations, as CDMOs must continuously adapt to evolving compliance requirements. Capacity constraints are another significant challenge, with growing demand for large molecule contract manufacturing outpacing available production infrastructure. To address this, CDMOs are expanding their manufacturing footprints and investing in flexible production platforms, such as modular bioprocessing and continuous manufacturing technologies. The complexity of large molecule drug development also requires advanced analytical capabilities and expertise in process characterization, adding another layer of technical challenges. Additionally, workforce shortages in bioprocess engineering and regulatory compliance are impacting the ability of CDMOs to scale operations efficiently. Overcoming these challenges will be critical for ensuring sustainable growth and meeting the increasing demand for large molecule CDMO services.

What Is Driving the Expansion of the Large Molecule CDMO Market?

The growth in the large molecule CDMO market is driven by several factors, including the rising adoption of biologics, increasing biopharmaceutical investments, and advances in manufacturing technologies. The surge in demand for monoclonal antibodies, vaccines, and cell and gene therapies is propelling the need for specialized CDMO services that can handle complex biomanufacturing processes. The expansion of contract development partnerships between pharmaceutical companies and CDMOs is accelerating, as firms seek cost-effective and scalable solutions for drug production. Regulatory agencies are also playing a key role in driving market growth by establishing guidelines that promote quality, safety, and efficiency in biologics manufacturing. The increasing trend toward personalized medicine and precision biologics is encouraging CDMOs to invest in flexible manufacturing technologies, such as single-use systems and high-throughput screening platforms. Additionally, advancements in process automation, AI-driven analytics, and smart bioprocessing are enhancing efficiency and reducing production costs. As pharmaceutical companies continue to shift toward outsourcing to mitigate risks and optimize resources, the large molecule CDMO market is poised for sustained growth, shaping the future of biopharmaceutical manufacturing.

SCOPE OF STUDY:

The report analyzes the Large Molecule Drug Substance CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Contract Manufacturing Service, Contract Development Service); Source (Mammalian Source, Microbial Source, Other Sources); End-User (Biotech Companies End-User, CRO End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abzena
  • AGC Biologics
  • Avid Bioservices
  • BioVectra
  • Boehringer Ingelheim BioXcellence
  • Catalent, Inc.
  • Emergent BioSolutions
  • Eurofins Scientific
  • FUJIFILM Diosynth Biotechnologies
  • JHL Biotech
  • KBI Biopharma
  • Lonza Group
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Siegfried Holding AG
  • Syngene International
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Large Molecule Drug Substance CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Shift Toward Biologics and Biosimilars Expands Addressable Market Opportunity for Large Molecule CDMOs
    • Escalating Complexity of Biologic Drug Substances Strengthens Business Case for Specialized CDMO Capabilities
    • Rising R&D Investment in Monoclonal Antibodies Spurs Demand for Large Molecule Manufacturing Partnerships
    • Growing Pipeline of Cell and Gene Therapies Propels Growth in Large Molecule CDMO Collaborations
    • Outsourcing Trends Among Small and Mid-sized Biopharma Drives Adoption of End-to-End CDMO Services
    • Regulatory Focus on GMP Compliance Throws the Spotlight on Quality-Centric CDMO Partners
    • Accelerated Drug Development Timelines Generate Demand for Agile and Scalable CDMO Infrastructure
    • Capacity Expansion Initiatives by Leading CDMOs Sustain Growth in Contract Manufacturing Capabilities
    • Biotech Startup Ecosystem Growth Expands Market Opportunities for Specialized Large Molecule CDMOs
    • Strategic Partnerships and Licensing Deals Strengthen the Business Case for Outsourced Drug Substance Manufacturing
    • Technological Advancements in Upstream and Downstream Processing Drive Efficiency and Quality in CDMO Operations
    • Integration of Single-Use Bioreactors and Modular Facilities Drives Adoption of Flexible Manufacturing Solutions
    • Increasing Focus on Sustainability and Green Manufacturing Practices Creates Opportunities for Differentiated CDMO Offerings
    • Rising Demand for High-Titer Expression Systems Accelerates CDMO Innovation in Bioprocess Optimization
    • Expansion of CDMO Presence in Emerging Markets Spurs Competitive Manufacturing Cost Advantages
    • Regulatory Harmonization and Fast-Track Approvals Propel CDMO Involvement in Global Biologic Launch Programs
    • Advanced Analytics and Digital Manufacturing Solutions Drive Operational Transparency and Process Control
    • Demand for Integrated Development-to-Commercialization Services Enhances CDMO Value Proposition
    • Growing Requirements for Process Characterization and Validation Expand Scope of CDMO Offerings
    • Increasing Importance of Cold Chain Logistics Infrastructure Strengthens CDMO Engagement Across the Supply Chain
    • Pandemic Preparedness and Vaccine Manufacturing Initiatives Spur Investment in Large Molecule CDMO Capacity
    • Shift Toward Personalized Biologic Therapies Drives Demand for Customizable CDMO Platforms
    • High Cost of In-House Biologics Infrastructure Strengthens Economic Case for CDMO Engagement
    • Competitive Differentiation Through Specialized Capabilities in ADCs and Fusion Proteins Propels Market Leadership
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Large Molecule Drug Substance CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Contract Manufacturing Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Contract Manufacturing Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Contract Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Contract Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Mammalian Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Microbial Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Microbial Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Microbial Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Biotech Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for CRO End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for CRO End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for CRO End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • JAPAN
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • CHINA
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • EUROPE
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • FRANCE
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • GERMANY
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • INDIA
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Large Molecule Drug Substance CDMO by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030
  • AFRICA
    • Large Molecule Drug Substance CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Large Molecule Drug Substance CDMO by Service - Contract Manufacturing Service and Contract Development Service Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Large Molecule Drug Substance CDMO by Service - Percentage Breakdown of Value Sales for Contract Manufacturing Service and Contract Development Service for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Large Molecule Drug Substance CDMO by Source - Mammalian Source, Microbial Source and Other Sources Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Large Molecule Drug Substance CDMO by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Large Molecule Drug Substance CDMO by End-user - Biotech Companies End-User, CRO End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Large Molecule Drug Substance CDMO by End-user - Percentage Breakdown of Value Sales for Biotech Companies End-User, CRO End-User and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제